S-DUAL
LIVE

Serial Number

79365471

Owner

Samsung Biologics Co., Ltd.

Attorney

Brian P. Gregg

Filing Date

Jan 31, 2023

Add to watchlist:

No watchlists yet
View on USPTO

S-DUAL Trademark

Serial Number: 79365471 • Registration: 7876915

S-DUAL is a trademark filed by Samsung Biologics Co., Ltd. on January 31, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Samsung Biologics Co., Ltd. (26 trademarks)

300, Songdo bio-daero,

Entity Type: 03

Trademark Details

Filing Date

January 31, 2023

Registration Date

August 5, 2025

Published for Opposition

June 17, 2025

Goods & Services

Reagents for measurement of HBs antibody for medical purposes; crude medicines for the treatment of cardiovascular diseases; pharmaceutical preparations for activating cellular function; colostral antibodies for veterinary purposes; chemico-pharmaceutical preparations for treating ocular diseases; chemical preparations for use in DNA analysis for medical purposes; bacterial preparations for medical and veterinary use; chemical preparations for medical or veterinary purposes, namely, for bispecific or multispecific antibodies and derivatives thereof, to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases, neurological disorder and for related diagnostic or therapeutic use, and for use in related assays; biotechnological preparations being reagents for medical purposes; biological reagents for medical purposes; biochemical preparations for medical use, namely, for bispecific or multispecific antibodies and derivatives thereof, to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases, neurological disorder and for related diagnostic or therapeutic use, and for use in related assays; reagents for medical use; reagent paper for medical purposes; bispecific colostral antibody for medical purposes; medical diagnostic test strips for use in the field of blood analysis; trace element preparations for human use, namely, dietary and nutritional supplements; clinical medical reagents; therapeutic drugs for treating cancer and drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; antigens being pharmaceutical preparations for stimulating immune responses; colostral antibodies for medical purposes

Multiple fusion proteins in raw material form for scientific or medical research use; diagnostic reagents for scientific or research use; enzymes for scientific or research purposes; bispecific antibody being monoclonal antibodies for in vitro scientific or medical research use; cell culture reagents for scientific and research use; monoclonal antibodies for in vitro scientific purposes; microorganisms for scientific or laboratory purposes, other than for medical and veterinary use; biological preparations for scientific or industrial laboratory purposes; fusion proteins in raw material form for scientific or medical research laboratory purposes; polymerase for nucleic acid for scientific or laboratory purposes; biochemical preparations for scientific purposes; double antibody reagents for scientific purposes; double antibody reagents for scientific purposes in biotechnological product development; biological preparations for use in biotechnology, other than for medical and veterinary use; biochemical catalysts; chemical reagents for use in genetic research for non-medical purposes

Research relating to science, namely, scientific research; multiple nucleic acid scientific analysis; molecular scientific analysis; development of biotechnology; biochemical analysis; drug discovery services; new product design services; pharmaceutical research and development; clinical research in the field of medicine; services for assessing the efficiency of pharmaceuticals, namely, product quality testing; fusion protein scientific analysis; computer programming services in the medical field; medical laboratories; computer project management services relating to imaging medical data; medicine research being medical research; analysis and evaluation of medical product development, namely, product quality testing; providing scientific information on the testing, inspection and research of medical products; scientific laboratory services relating to the production of bispecific antibody; drug development of bispecific antibody; scientific research and development for double antibody reagent; evaluating of clinical trial progress, namely, conducting clinical trials for others; conducting clinical trials for others

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 5, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 12, 2026 FICS
FINAL DISPOSITION PROCESSED
Feb 12, 2026 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 5, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 5, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 5, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 17, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 17, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 11, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 16, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
May 15, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 15, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
May 15, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 15, 2025 CNEA
ASSIGNED TO EXAMINER
May 6, 2025 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
May 6, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 6, 2025 CRFA
ASSIGNED TO EXAMINER
Nov 30, 2024 DOCK
ASSIGNED TO EXAMINER
Nov 30, 2024 DOCK
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Aug 31, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 14, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Aug 14, 2024 OPNR
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 20, 2024 TROA
NOTICE OF REVIVAL - E-MAILED
May 20, 2024 NREV
PETITION TO REVIVE-GRANTED
May 20, 2024 PETG
TEAS PETITION TO REVIVE RECEIVED
May 20, 2024 PROA
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
May 16, 2024 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
May 16, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 16, 2024 ABN2
REFUSAL PROCESSED BY IB
Nov 22, 2023 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 2, 2023 RFCS
REFUSAL PROCESSED BY MPU
Nov 2, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 2, 2023 RFCR
NON-FINAL ACTION WRITTEN
Nov 1, 2023 CNRT
ASSIGNED TO EXAMINER
Oct 30, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 24, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 20, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 16, 2023 REPR